A man poses with an Apple iPhone 12 in a mobile phone store in Nantes, France, September 13, 2023.
| Photo Credit: Reuters

A systematic review into the potential health effects from radio wave exposure has shown mobile phones are not linked to brain cancer. The review was commissioned by the World Health Organization and is published today in the journal Environment International.

Mobile phones are often held against the head during use. And they emit radio waves, a type of non-ionising radiation. These two factors are largely why the idea mobile phones might cause brain cancer emerged in the first place.

The possibility that mobile phones might cause cancer has been a long-standing concern. Mobile phones – and wireless tech more broadly – are a major part of our daily lives. So it’s been vital for science to address the safety of radio wave exposure from these devices.

Over the years, the scientific consensus has remained strong – there’s no association between mobile phone radio waves and brain cancer, or health more generally.

Radiation as a possible carcinogen

Despite the consensus, occasional research studies have been published that suggested the possibility of harm.

In 2011, the International Agency for Research on Cancer (IARC) classified radio wave exposure as a possible carcinogen to humans. The meaning of this classification was largely misunderstood and led to some increase in concern.

IARC is part of the World Health Organization. Its classification of radio waves as a possible carcinogen was largely based on limited evidence from human observational studies. Also known as epidemiological studies, they observe the rate of disease and how it may be caused in human populations.

Observational studies are the best tool researchers have to investigate long-term health effects in humans, but the results can often be biased.

The IARC classification relied on previous observational studies where people with brain cancer reported they used a mobile phone more than they actually did. One example of this is known as the INTERPHONE study.

This new systematic review of human observational studies is based on a much larger data set compared to what the IARC examined in 2011.

It includes more recent and more comprehensive studies. This means we can now be more confident that exposure to radio waves from mobile phones or wireless technologies is not associated with an increased risk of brain cancer.

No association

The new review forms part of a series of systematic reviews commissioned by the World Health Organization to look more closely at possible health effects associated with exposure to radio waves.

This systematic review provides the strongest evidence to date that radio waves from wireless technologies are not a hazard to human health.

It is the most comprehensive review on this topic – it considered more than 5,000 studies, of which 63, published between 1994 and 2022, were included in the final analysis. The main reason studies were excluded was that they were not actually relevant; this is very normal with search results from systematic reviews.

No association between mobile phone use and brain cancer, or any other head or neck cancer, was found.

There was also no association with cancer if a person used a mobile phone for ten or more years (prolonged use). How often they used it – either based on the number of calls or the time spent on the phone – also didn’t make a difference.

Importantly, these findings align with previous research. It shows that, although the use of wireless technologies has massively increased in the past few decades, there has been no rise in the incidence of brain cancers.

A good thing

Overall, the results are very reassuring. They mean that our national and international safety limits are protective. Mobile phones emit low-level radio waves below these safety limits, and there is no evidence exposure to these has an impact on human health.

Despite this, it is important that research continues. Technology is developing at a rapid pace. With this development comes the use of radio waves in different ways using different frequencies. It is therefore essential that science continues to ensure radio wave exposure from these technologies remains safe.

The challenge we now face is making sure this new research counteracts the persistent misconceptions and misinformation out there regarding mobile phones and brain cancer.

There remains no evidence of any established health effects from exposures related to mobile phones, and that is a good thing.

This article is republished from The Conversation under a Creative Commons license. Read the original article.

There is no link between mobile phone use and increased brain cancer risk, according to a new World Health Organization-commissioned review of the available published evidence worldwide.

Despite the huge rise in the use of wireless technology, there has not been a corresponding rise in the incidence of brain cancers, the review, published on Tuesday, found. That applies even to people who make long phone calls or those who have used mobile phones for more than a decade.

The final analysis included 63 studies from 1994-2022, assessed by 11 investigators from 10 countries, including the Australian government’s radiation protection authority.

The work assessed the effects of radiofrequency, used in mobile phones as well as TV, baby monitors and radar, co-author Mark Elwood, professor of cancer epidemiology at the University of Auckland, New Zealand, said.

“None of the major questions studied showed increased risks,” he said. The review looked at cancers of the brain in adults and children, as well as cancer of the pituitary gland, salivary glands and leukemias, and risks linked to mobile phone use, base stations, or transmitters, as well as occupational exposure. Other cancer types will be reported separately.

The review follows other similar work. The WHO and other international health bodies have said previously there is no definitive evidence of adverse health effects from the radiation used by mobile phones, but called for more research. It is currently classified as “possibly carcinogenic”, or class 2B, by the International Agency for Research on Cancer (IARC), a category used when the agency cannot rule out a potential link.

The agency’s advisory group has called for the classification to be re-evaluated as soon as possible given the new data since its last assessment in 2011.

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

Scientists have created a novel method for detecting brain cancer that is faster and less invasive than typical surgical biopsies. The newly developed ‘liquid biopsy’ uses only 100 microlitres of blood and can detect biomarkers associated with glioblastoma-the most prevalent and lethal type of brain tumour-in just one hour.

The test, which is more accurate than any known approach for detecting glioblastoma, is described by its researchers as having “near turn-key functionality.” A team of researchers from the University of Notre Dame in the United States collaborated with Australian scientists to develop the new approach. While still in its early stages, this proof of concept marks a huge step forward in brain cancer diagnosis.

According to a release by University Of Notre Dam, the average glioblastoma patient survives 12-18 months after diagnosis. The crux of the diagnostic is a biochip that uses electrokinetic technology to detect biomarkers, or active Epidermal Growth Factor Receptors (EGFRs), which are overexpressed in certain cancers such as glioblastoma and found in extracellular vesicles.

“Extracellular vesicles or exosomes are unique nanoparticles secreted by cells. They are big – 10 to 50 times bigger than a molecule – and they have a weak charge. Our technology was specifically designed for these nanoparticles, using their features to our advantage,” said Hsueh-Chia Chang, the Bayer Professor of Chemical and Biomolecular Engineering at Notre Dame and lead author of the study about the diagnostic published in Communications Biology.

The challenge for researchers was two-fold: to develop a process that could distinguish between active and non-active EGFRs, and create a diagnostic technology that was sensitive yet selective in detecting active EGFRs on extracellular vesicles from blood samples.

Brain cancers remain among the most challenging tumors to treat. They often don’t respond to traditional treatments because many chemotherapies are unable to penetrate the protective barrier around the brain. Other treatments like radiation and surgery can leave patients with lifelong debilitating side effects.

As a result, brain cancer is the leading cause of cancer-related death in children. Brain tumors in children frequently do not respond to treatments developed for adults, likely due to the fact that pediatric brain cancers are not as well-studied as adult brain cancers. There is an urgent need to develop new treatments specific to children.

We developed a new messenger-RNA, or mRNA, cancer vaccine, described in newly published research, that can deliver treatments more effectively in children who have brain cancer and teach their immune systems to fight back.

How do cancer vaccines work?

The immune system is a complex network of cells, tissues and organs whose primary function is to continuously surveil the body for threats posed by foreign invaders – pathogens that damage tissues and make you sick. It accomplishes this by recognizing antigens, or abnormal proteins or molecules, on pathogens. T cells that recognize these antigens seek out and destroy the pathogens.

Your immune system also protects you from domestic threats like cancer. Over time, your cells sustain DNA damage from either internal or external stressors, leading to mutations. The proteins and molecules produced from mutated DNA look quite different from the ones cells typically produce, so your immune system can recognize them as antigens. Cancer develops when cells accumulate mutations that enable them to continue to grow and divide while simultaneously going undetected by the immune system.

In 1991, scientists identified the first tumor antigen, helping lay the framework for modern-day immunotherapy. Since then, researchers have identified many new tumor antigens, facilitating the development of cancer vaccines. Broadly, cancer vaccines deliver tumor antigens into the body to teach the immune system to recognize and attack cancer cells that display those antigens. Although all cancer vaccines conceptually work very similarly, they each significantly vary in the way they are developed and the number and combination of antigens they carry.

One of the biggest differences among cancer vaccines is how they are created. Some vaccines use protein fragments, or peptides, of tumor antigens that are directly given to patients. Other vaccines use viruses reengineered to express cancer antigens. Even more complex are vaccines where a patient’s own immune cells are collected and trained to recognize cancer antigens in a laboratory before being delivered back to the patient.

Currently, there is a lot of excitement and focus among researchers on developing mRNA-based cancer vaccines. Whereas DNA is the blueprint of which proteins to make, mRNA is a copy of the blueprint that tells cells how to build these proteins. Thus, researchers can use mRNA to create blueprint copies of potential antigens.

mRNA cancer vaccines

The COVID-19 pandemic brought significant attention to the potential of using mRNA-based vaccines to stimulate the immune system and provide protection against the antigens they encode for. But researchers have been investigating the use of mRNA vaccines for treating various cancers since before the pandemic.

Our teamof scientists in the Brain Tumor Immunotherapy Program at University of Florida has spent the past 10 years developing and optimizing mRNA vaccines to treat brain cancer.

Cancer vaccines have faced significant challenges. One key hurdle is that these vaccines may not always trigger a strong enough immune response to eradicate the cancer completely. Moreover, tumors are not made up of one type of cancer cell, but rather a complex mix of cancer cells that each harbors its own unique cocktail of mutations.

Our cancer vaccine seeks to address these issues in a number of ways.

First, we designed our vaccines by using the RNA of a patients’ own cancer cells as a template for the mRNA inside our nanoparticles. We also packaged our cancer vaccine inside of nanoparticles made up of specialized lipids, or fat molecules. We maximized the amount of mRNA packaged within each nanoparticle by sandwiching them between lipid layers like the layers of an onion. In this way, we increase the likelihood that the mRNA molecules in our nanoparticles produce enough tumor antigens from that patient’s cancer to activate an immune response.

Also, instead of injecting nanoparticles into the skin, muscle or directly into the tumor, as is commonly done for many therapeutic cancer vaccines, our mRNA nanoparticles are injected into the bloodstream. From there, they travel to organs throughout the body involved in the immune response to teach the body to fight against the cancer. By doing so, we’ve found that the immune system launches a near immediate and powerful response. Within six hours of receiving the vaccine, there is a significant increase in the amount of blood markers connected to immune activation.

Looking to the future

Our mRNA-based vaccines are currently undergoing early-phase clinical trials to treat real patients with brain cancer.

We administered our mRNA-based vaccine to four adult patients with glioblastoma who had relapsed after previous treatment. All patients survived several months longer than the expected average survival at this advanced stage of illness. We expect to treat children with a type of brain tumor called pediatric high-grade glioma by the end of the year.

Importantly, mRNA vaccines can be developed to treat any kind of cancer, including childhood brain tumors. Our Pediatric Cancer Immunotherapy Initiative focuses on developing new immune-based therapies for children afflicted with cancer. After developing an mRNA vaccine for glioma in chidren, we will expand to treat other kinds of pediatric brain cancers like medulloblastoma and potentially treat other kinds of cancers like skin cancer and bone cancer.

We are hopeful that mRNA-based vaccines may lead to more children being cured of their brain tumors.

Christina von Roemeling, Assistant Professor of Neurosurgery, University of Florida and John Ligon, Assistant Professor of Hematology, University of Florida

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Image used for representational purpose only.
| Photo Credit: AP

When Herve found out he had glioblastoma — the most aggressive form of brain cancer — at the age of 40, he made a deal with himself.

“I said to myself: it is serious, but you are at war — and you’re going to win,” the French teacher, who did not want to give his surname, said.

Eight years later, following surgery to remove the tumour, radiotherapy and chemotherapy, Herve is still winning his war.

He is just one of the thousands of people across the world to have survived an extremely deadly cancer for which there is no known cure.

“We call them outliers,” said Nicolas Wolikow, the CEO and co-founder of the Paris-based firm Cure51.

“For unknown reasons, when these people face an illness they take a completely different trajectory from other people,” he said.

The start-up is working on creating “the first global clinical and molecular database of exceptional survivors” of cancer, according to its website.

So far, the firm has partnered with 50 cancer centres around the world to get data from a wider variety of survivors and found 1300 patients to be part of the project.

Once the data is collected “we will begin analysing medical reports, images, tumour cells,” Mr. Wolikow said.

The ultimate goal is to create new drugs or treatments that mimic the molecular characteristics of those few who do survive these killer cancers.